Discovery Labs boosted as US FDA removes clinical trial requirement for Surfaxin
This article was originally published in Scrip
Executive Summary
The US FDA has told Discovery Laboratories that it needs only to perform additional preclinical studies, rather than a clinical trial, in order to gain an approval for Surfaxin (lucinactant), its troubled treatment for the prevention of respiratory distress syndrome (RDS) in premature infants.
You may also be interested in...
P&G to co-promote Somaxon's Silenor in the US
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GSK's shingles vaccine begins Phase III studies
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
Optimer's fidaxomicin filing accepted in EU
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.